Evotec SE

EVTA.F·Frankfurt
Compare
1.26000.0000 (0.00%)today
As of Oct 23, 8:03 AM CEST · May be delayed up to 15 min · EUR

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close1.2600
Open1.2600
Day range—
52-week range0.98003.5400
Off day high0.00%
Off 52-week high−64.41%
Volume5.00K
Avg. volume (3M)685
Market cap447.79M
EPS (TTM)-0.5500
Forward P/E—
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)—
Shares outstanding355.39M
Short interest—
Earnings dateNov 5, 2026
Analyst target—
Profit margin—

Against its peers

Compare in full ›
EVTA.F NOVARTIND.BO ALVO GUD.TO EII.F EMCURE.BO
Market cap 447.79M 45.30B 1.63B 1.14B 8.45B 335.47B
P/E (TTM) — 46.3 — 77.4 38.4 33.1
Forward P/E — — 19.9 44.7 25.4 22.8
Price/book 0.7 5.5 -8.5 1.4 1.7 6.8
Dividend yield — — — — 3.22% 0.20%
1-year change −64.20% +95.36% −42.98% +100.69% +11.88% +31.58%
Today 0.00% +8.78% −4.38% −0.77% +6.29% −0.94%

The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.

Latest news

All EVTA.F news ›
european-biotechnology.com·Positive

Evotec fills CSO vacancy; Sibylla and AL-S Pharma name new CEOs

Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: a swift scientific leadership change at Evotec, a broader reshuffle at…

StreetInsider.com·

Evotec names Dr. Joanna Holbrook as chief scientific officer

StreetInsider Evotec SE (NASDAQ: EVO) has appointed Dr. Joanna Holbrook as Chief Scientific Officer and member of its Management Board, effective November 1, 2026, according to a company statement. In her new role, Dr. Holbrook will…

Stock Titan·

Evotec SE shareholder sells 11.5M shares in exit

A €2.5109-per-share block trade ends an investment in Evotec SE (EVO). Stock Titan - [SCHEDULE 13D/A] Evotec SE Amended Major Shareholder Report Evotec SE shareholder sells 11.5M shares in exit Three reporting persons ceased to be…

Stock Titan·

Evotec preliminary nine-month revenue near €465M

Evotec said preliminary nine-month 2026 figures exceeded market expectations and reaffirmed its full-year revenue and adjusted EBITDA guidance. Evotec SE (EVO) announced preliminary, unaudited Group revenue of approximately €465.0 million…

From articles in the 4Search news index.

In the news

12mentions in 30 days
12with it in the headline
Mixedsentiment

Most coverage from

  1. tradingview.com4
  2. stocktitan.net3
  3. european-biotechnology.com2
  4. defenseworld.net1
  5. streetinsider.com1

Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use.